Stay updated with breaking news from Opiant Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As we step into the third month of the second quarter, let's take a quick look at the regulatory news that made headlines in May and offer you a sneak peek into the anticipated FDA decisions coming up in June.
The U.S. Food and Drug Administration approved Opiant Pharmaceuticals' Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric patients 12 years of age and older.
Independent advisors Wednesday, recommended the U.S. Food and Drug Administration approve over the counter sales of naloxone, which is commonly used to reverse opioid overdoses.
FinancialContent fully hosted finance channel
(RTTNews) - Shares of Opiant Pharmaceuticals Inc. (OPNT) have lost nearly 25% of their value so far this year and trade around $25. Opiant Pharma...